Chern CU, Li JY, Tsui KH, et al. - Researchers investigated the effectiveness of dual-trigger for final oocyte maturation on the in vitro fertilization (IVF) outcomes of patients who fulfill the Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 4 criteria. In this retrospective cohort study, 384 cycles fulfilling the POSEIDON group 4 criteria were examined. The gonadotropin-releasing hormone (GnRH) antagonist protocol was used in IVF treatment of included patients. The study group was comprised of 194 cycles that received dual-trigger (human chorionic gonadotropin [hCG] plus GnRH-agonist) for final oocyte maturation and the control group was comprised of 114 cycles where final oocyte maturation was performed with only hCG. In terms of IVF outcomes, significantly higher number of retrieved oocytes, metaphase II oocytes, fertilized oocytes, day-3 embryos, and top-quality day-3 embryos were reported among those in the dual trigger group. Further, the dual trigger group had a statistically significant improvement in clinical pregnancy rate and live birth rate. Findings thereby support the possible value of dual trigger for final oocyte maturation for enhancing clinical pregnancy rates and live birth rates of IVF cycles in patients fulfilling the POSEIDON group 4 criteria.